Combining immunotherapy with targeted therapy has increasingly become an appealing
therapeutic paradigm for cancer treatment due to its great potential for generating durable …

Approximately, 50% of human melanomas are driven by BRAF mutations, which produce
tumors that are highly immunosuppressive and often resistant to vaccine therapy. We …

The BRAF mutant, BRAFV600E, is expressed in nearly half of melanomas, and oral BRAF
inhibitors induce substantial tumor regression in patients with BRAFV600E metastatic …

Purpose: An intact immune system likely contributes to the outcome of treatment and may be
important for clearance of drug-resistant tumor cells and for prevention of recurrence …

Serine/threonine‐protein kinase B‐raf (BRAF) mutations are found in 8–15% of colorectal
cancer patients and identify a subset of tumors with poor outcome in the metastatic setting …

A three-drug combination to treat BRAF-mutant cancers | Nature Medicine Skip to main content
Thank you for visiting nature.com. You are using a browser version with limited support for …

A growing body of evidence suggests that BRAF inhibitors, in addition to their acute tumor
growth–inhibitory effects, can also promote immune responses to melanoma. The present …

Malignant melanoma is associated with poor clinical prognosis; however, novel molecular
and immune therapies are now improving patient outcomes. Almost 50% of melanomas …

We have recently discovered that BRAF inhibitors induce potent macrophage responses that
confer melanoma resistance to therapy. Our studies lay a foundation for the hypothesis that …

B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI,
predominantly expressed on mature B cells. Almost all B cell cancers are reported to …